Roche’s Ocrevus (ocrelizumab), a new drug designed to treat a form of multiple sclerosis for which no treatments are available, has been granted priority review status by the US Food and Drug Administration (FDA).
What is NewsMeBack?
NewsMeBack is the place for everyone who likes citizen journalism and social news, a place for you where you can put your news, events from everyday life, something interesting that happened in your life or else.
Log in to comment or register here.